世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
良性前立腺肥大症治療薬市場。世界の産業動向、シェア、サイズ、成長、機会、および2021-2026年の予測Benign Prostatic Hyperplasia Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026 The global benign prostatic hyperplasia treatment market reached a value of US$ 10.5 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 5.6% during 2021-2026. Kee... もっと見る
サマリーThe global benign prostatic hyperplasia treatment market reached a value of US$ 10.5 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 5.6% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.Benign prostatic hyperplasia (BPH) or benign prostatic hypertrophy refers to the non-cancerous enlargement of the prostate gland that causes blockage in the urethra. This condition causes difficulties in urine retention, bladder stones, incontinence due to overfilling, increased sensitivity of the bladder and infections in the urinary tract. Some of the commonly used treatment alternatives for BPH include prescription drugs, active observation or surveillance, mono drug and combined therapies, phytotherapies and minimally invasive (MI) and invasive surgeries. These surgeries are usually conducted through devices, such as resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents and implants. The increasing prevalence of urological disorders across the globe represents one of the key factors creating a positive outlook for the market. Furthermore, the rising geriatric population, which is more susceptible to such critical ailments, is providing a boost to the market growth. Healthcare providers use alpha-blockers to manage BPH by relaxing the prostate muscles and controlling the blood pressure of the patient. In line with this, rising health consciousness and awareness among the masses regarding the available treatment alternatives are also contributing to the market growth. Additionally, various advancements, such as the development of transurethral resection of the prostate (TURP) as an effective treatment procedure, are acting as other growth-inducing factors. TURP is an endoscopic electrosurgical procedure that involves removing a portion of the prostate gland to reduce obstruction caused by the abnormal growth. Other factors, including rising healthcare expenditure capacities of individuals, along with significant improvements in the healthcare infrastructure, especially in the developing countries, are anticipated to drive the market further. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global benign prostatic hyperplasia treatment market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on treatment type. Breakup by Treatment Type: Drug Class Alpha-Blockers 5-Alpha-reductase Inhibitors (5-ARIs) Phosphodiesterase-5 Enzyme Inhibitors Others Minimally Invasive Surgeries Transurethral Resection of the Prostate (TURP) Transurethral Incision of the Prostate (TUIP) Transurethral Microwave Thermotherapy (TUMT) Robotic Surgeries Prostatic Urethral Lifts Others Laser Therapy Others Breakup by Region: North America United States Canada Asia Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Allergan Plc (AbbVie Inc.), Asahi Kasei Corporation, Astellas Pharma Inc., Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG), Boston Scientific Corporation, GlaxoSmithKline Plc, Pfizer Inc., Sanofi S.A. and Teva Pharmaceutical Industries Ltd. Key Questions Answered in This Report: How has the global benign prostatic hyperplasia treatment market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global benign prostatic hyperplasia treatment market? What are the key regional markets? What is the breakup of the market based on the treatment type? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global benign prostatic hyperplasia treatment market and who are the key players? What is the degree of competition in the industry? 目次1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Benign Prostatic Hyperplasia Treatment Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Treatment Type 6.1 Drug Class 6.1.1 Market Trends 6.1.2 Major Types 6.1.2.1 Alpha-Blockers 6.1.2.2 5-Alpha-reductase Inhibitors (5-ARIs) 6.1.2.2 Phosphodiesterase-5 Enzyme Inhibitors 6.1.2.3 Others 6.1.3 Market Forecast 6.2 Minimally Invasive Surgeries 6.2.1 Market Trends 6.2.2 Major Types 6.2.2.1 Transurethral Resection of the Prostate (TURP) 6.2.2.2 Transurethral Incision of the Prostate (TUIP) 6.2.2.3 Transurethral Microwave Thermotherapy (TUMT) 6.2.2.4 Robotic Surgeries 6.2.2.5 Prostatic Urethral Lifts 6.2.2.6 Others 6.2.3 Market Forecast 6.3 Laser Therapy 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Others 6.4.1 Market Trends 6.4.2 Market Forecast 7 Market Breakup by Region 7.1 North America 7.1.1 United States 7.1.1.1 Market Trends 7.1.1.2 Market Forecast 7.1.2 Canada 7.1.2.1 Market Trends 7.1.2.2 Market Forecast 7.2 Asia Pacific 7.2.1 China 7.2.1.1 Market Trends 7.2.1.2 Market Forecast 7.2.2 Japan 7.2.2.1 Market Trends 7.2.2.2 Market Forecast 7.2.3 India 7.2.3.1 Market Trends 7.2.3.2 Market Forecast 7.2.4 South Korea 7.2.4.1 Market Trends 7.2.4.2 Market Forecast 7.2.5 Australia 7.2.5.1 Market Trends 7.2.5.2 Market Forecast 7.2.6 Indonesia 7.2.6.1 Market Trends 7.2.6.2 Market Forecast 7.2.7 Others 7.2.7.1 Market Trends 7.2.7.2 Market Forecast 7.3 Europe 7.3.1 Germany 7.3.1.1 Market Trends 7.3.1.2 Market Forecast 7.3.2 France 7.3.2.1 Market Trends 7.3.2.2 Market Forecast 7.3.3 United Kingdom 7.3.3.1 Market Trends 7.3.3.2 Market Forecast 7.3.4 Italy 7.3.4.1 Market Trends 7.3.4.2 Market Forecast 7.3.5 Spain 7.3.5.1 Market Trends 7.3.5.2 Market Forecast 7.3.6 Russia 7.3.6.1 Market Trends 7.3.6.2 Market Forecast 7.3.7 Others 7.3.7.1 Market Trends 7.3.7.2 Market Forecast 7.4 Latin America 7.4.1 Brazil 7.4.1.1 Market Trends 7.4.1.2 Market Forecast 7.4.2 Mexico 7.4.2.1 Market Trends 7.4.2.2 Market Forecast 7.4.3 Others 7.4.3.1 Market Trends 7.4.3.2 Market Forecast 7.5 Middle East and Africa 7.5.1 Market Trends 7.5.2 Market Breakup by Country 7.5.3 Market Forecast 8 SWOT Analysis 8.1 Overview 8.2 Strengths 8.3 Weaknesses 8.4 Opportunities 8.5 Threats 9 Value Chain Analysis 10 Porters Five Forces Analysis 10.1 Overview 10.2 Bargaining Power of Buyers 10.3 Bargaining Power of Suppliers 10.4 Degree of Competition 10.5 Threat of New Entrants 10.6 Threat of Substitutes 11 Price Analysis 12 Competitive Landscape 12.1 Market Structure 12.2 Key Players 12.3 Profiles of Key Players 12.3.1 Abbott Laboratories 12.3.1.1 Company Overview 12.3.1.2 Product Portfolio 12.3.1.3 Financials 12.3.1.4 SWOT Analysis 12.3.2 Allergan plc (AbbVie Inc.) 12.3.2.1 Company Overview 12.3.2.2 Product Portfolio 12.3.2.3 Financials 12.3.2.4 SWOT Analysis 12.3.3 Asahi Kasei Corporation 12.3.3.1 Company Overview 12.3.3.2 Product Portfolio 12.3.3.3 Financials 12.3.3.4 SWOT Analysis 12.3.4 Astellas Pharma Inc. 12.3.4.1 Company Overview 12.3.4.2 Product Portfolio 12.3.4.3 Financials 12.3.4.4 SWOT Analysis 12.3.5 Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG) 12.3.5.1 Company Overview 12.3.5.2 Product Portfolio 12.3.5.3 SWOT Analysis 12.3.6 Boston Scientific Corporation 12.3.6.1 Company Overview 12.3.6.2 Product Portfolio 12.3.6.3 Financials 12.3.6.4 SWOT Analysis 12.3.7 GlaxoSmithKline Plc 12.3.7.1 Company Overview 12.3.7.2 Product Portfolio 12.3.7.3 Financials 12.3.7.4 SWOT Analysis 12.3.8 Pfizer Inc. 12.3.8.1 Company Overview 12.3.8.2 Product Portfolio 12.3.8.3 Financials 12.3.8.4 SWOT Analysis 12.3.9 Sanofi S.A. 12.3.9.1 Company Overview 12.3.9.2 Product Portfolio 12.3.9.3 Financials 12.3.9.4 SWOT Analysis 12.3.10 Teva Pharmaceutical Industries Ltd. 12.3.10.1 Company Overview 12.3.10.2 Product Portfolio 12.3.10.3 Financials 12.3.10.4 SWOT Analysis
SummaryThe global benign prostatic hyperplasia treatment market reached a value of US$ 10.5 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 5.6% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.Benign prostatic hyperplasia (BPH) or benign prostatic hypertrophy refers to the non-cancerous enlargement of the prostate gland that causes blockage in the urethra. This condition causes difficulties in urine retention, bladder stones, incontinence due to overfilling, increased sensitivity of the bladder and infections in the urinary tract. Some of the commonly used treatment alternatives for BPH include prescription drugs, active observation or surveillance, mono drug and combined therapies, phytotherapies and minimally invasive (MI) and invasive surgeries. These surgeries are usually conducted through devices, such as resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents and implants. The increasing prevalence of urological disorders across the globe represents one of the key factors creating a positive outlook for the market. Furthermore, the rising geriatric population, which is more susceptible to such critical ailments, is providing a boost to the market growth. Healthcare providers use alpha-blockers to manage BPH by relaxing the prostate muscles and controlling the blood pressure of the patient. In line with this, rising health consciousness and awareness among the masses regarding the available treatment alternatives are also contributing to the market growth. Additionally, various advancements, such as the development of transurethral resection of the prostate (TURP) as an effective treatment procedure, are acting as other growth-inducing factors. TURP is an endoscopic electrosurgical procedure that involves removing a portion of the prostate gland to reduce obstruction caused by the abnormal growth. Other factors, including rising healthcare expenditure capacities of individuals, along with significant improvements in the healthcare infrastructure, especially in the developing countries, are anticipated to drive the market further. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global benign prostatic hyperplasia treatment market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on treatment type. Breakup by Treatment Type: Drug Class Alpha-Blockers 5-Alpha-reductase Inhibitors (5-ARIs) Phosphodiesterase-5 Enzyme Inhibitors Others Minimally Invasive Surgeries Transurethral Resection of the Prostate (TURP) Transurethral Incision of the Prostate (TUIP) Transurethral Microwave Thermotherapy (TUMT) Robotic Surgeries Prostatic Urethral Lifts Others Laser Therapy Others Breakup by Region: North America United States Canada Asia Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Allergan Plc (AbbVie Inc.), Asahi Kasei Corporation, Astellas Pharma Inc., Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG), Boston Scientific Corporation, GlaxoSmithKline Plc, Pfizer Inc., Sanofi S.A. and Teva Pharmaceutical Industries Ltd. Key Questions Answered in This Report: How has the global benign prostatic hyperplasia treatment market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global benign prostatic hyperplasia treatment market? What are the key regional markets? What is the breakup of the market based on the treatment type? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global benign prostatic hyperplasia treatment market and who are the key players? What is the degree of competition in the industry? Table of Contents1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Benign Prostatic Hyperplasia Treatment Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Treatment Type 6.1 Drug Class 6.1.1 Market Trends 6.1.2 Major Types 6.1.2.1 Alpha-Blockers 6.1.2.2 5-Alpha-reductase Inhibitors (5-ARIs) 6.1.2.2 Phosphodiesterase-5 Enzyme Inhibitors 6.1.2.3 Others 6.1.3 Market Forecast 6.2 Minimally Invasive Surgeries 6.2.1 Market Trends 6.2.2 Major Types 6.2.2.1 Transurethral Resection of the Prostate (TURP) 6.2.2.2 Transurethral Incision of the Prostate (TUIP) 6.2.2.3 Transurethral Microwave Thermotherapy (TUMT) 6.2.2.4 Robotic Surgeries 6.2.2.5 Prostatic Urethral Lifts 6.2.2.6 Others 6.2.3 Market Forecast 6.3 Laser Therapy 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Others 6.4.1 Market Trends 6.4.2 Market Forecast 7 Market Breakup by Region 7.1 North America 7.1.1 United States 7.1.1.1 Market Trends 7.1.1.2 Market Forecast 7.1.2 Canada 7.1.2.1 Market Trends 7.1.2.2 Market Forecast 7.2 Asia Pacific 7.2.1 China 7.2.1.1 Market Trends 7.2.1.2 Market Forecast 7.2.2 Japan 7.2.2.1 Market Trends 7.2.2.2 Market Forecast 7.2.3 India 7.2.3.1 Market Trends 7.2.3.2 Market Forecast 7.2.4 South Korea 7.2.4.1 Market Trends 7.2.4.2 Market Forecast 7.2.5 Australia 7.2.5.1 Market Trends 7.2.5.2 Market Forecast 7.2.6 Indonesia 7.2.6.1 Market Trends 7.2.6.2 Market Forecast 7.2.7 Others 7.2.7.1 Market Trends 7.2.7.2 Market Forecast 7.3 Europe 7.3.1 Germany 7.3.1.1 Market Trends 7.3.1.2 Market Forecast 7.3.2 France 7.3.2.1 Market Trends 7.3.2.2 Market Forecast 7.3.3 United Kingdom 7.3.3.1 Market Trends 7.3.3.2 Market Forecast 7.3.4 Italy 7.3.4.1 Market Trends 7.3.4.2 Market Forecast 7.3.5 Spain 7.3.5.1 Market Trends 7.3.5.2 Market Forecast 7.3.6 Russia 7.3.6.1 Market Trends 7.3.6.2 Market Forecast 7.3.7 Others 7.3.7.1 Market Trends 7.3.7.2 Market Forecast 7.4 Latin America 7.4.1 Brazil 7.4.1.1 Market Trends 7.4.1.2 Market Forecast 7.4.2 Mexico 7.4.2.1 Market Trends 7.4.2.2 Market Forecast 7.4.3 Others 7.4.3.1 Market Trends 7.4.3.2 Market Forecast 7.5 Middle East and Africa 7.5.1 Market Trends 7.5.2 Market Breakup by Country 7.5.3 Market Forecast 8 SWOT Analysis 8.1 Overview 8.2 Strengths 8.3 Weaknesses 8.4 Opportunities 8.5 Threats 9 Value Chain Analysis 10 Porters Five Forces Analysis 10.1 Overview 10.2 Bargaining Power of Buyers 10.3 Bargaining Power of Suppliers 10.4 Degree of Competition 10.5 Threat of New Entrants 10.6 Threat of Substitutes 11 Price Analysis 12 Competitive Landscape 12.1 Market Structure 12.2 Key Players 12.3 Profiles of Key Players 12.3.1 Abbott Laboratories 12.3.1.1 Company Overview 12.3.1.2 Product Portfolio 12.3.1.3 Financials 12.3.1.4 SWOT Analysis 12.3.2 Allergan plc (AbbVie Inc.) 12.3.2.1 Company Overview 12.3.2.2 Product Portfolio 12.3.2.3 Financials 12.3.2.4 SWOT Analysis 12.3.3 Asahi Kasei Corporation 12.3.3.1 Company Overview 12.3.3.2 Product Portfolio 12.3.3.3 Financials 12.3.3.4 SWOT Analysis 12.3.4 Astellas Pharma Inc. 12.3.4.1 Company Overview 12.3.4.2 Product Portfolio 12.3.4.3 Financials 12.3.4.4 SWOT Analysis 12.3.5 Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG) 12.3.5.1 Company Overview 12.3.5.2 Product Portfolio 12.3.5.3 SWOT Analysis 12.3.6 Boston Scientific Corporation 12.3.6.1 Company Overview 12.3.6.2 Product Portfolio 12.3.6.3 Financials 12.3.6.4 SWOT Analysis 12.3.7 GlaxoSmithKline Plc 12.3.7.1 Company Overview 12.3.7.2 Product Portfolio 12.3.7.3 Financials 12.3.7.4 SWOT Analysis 12.3.8 Pfizer Inc. 12.3.8.1 Company Overview 12.3.8.2 Product Portfolio 12.3.8.3 Financials 12.3.8.4 SWOT Analysis 12.3.9 Sanofi S.A. 12.3.9.1 Company Overview 12.3.9.2 Product Portfolio 12.3.9.3 Financials 12.3.9.4 SWOT Analysis 12.3.10 Teva Pharmaceutical Industries Ltd. 12.3.10.1 Company Overview 12.3.10.2 Product Portfolio 12.3.10.3 Financials 12.3.10.4 SWOT Analysis
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（その他）の最新刊レポート
IMARC Services Private Limited. 社の最新刊レポート
本レポートと同じKEY WORD（industry）の最新刊レポート
よくあるご質問IMARC Services Private Limited.社はどのような調査会社ですか?インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/10/15 10:26 150.67 円 164.75 円 199.57 円 |
